As of 2025-07-10, the EV/EBITDA ratio of Alnylam Pharmaceuticals Inc (ALNY) is -854.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Alnylam's latest enterprise value is 41,404.74 mil USD. Alnylam's TTM EBITDA according to its financial statements is -48.46 mil USD. Dividing these 2 quantities gives us the above Alnylam EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 9.8x | 8.1x |
| Forward P/E multiples | 7.5x - 10.3x | 8.0x |
| Fair Price | (2.90) - (3.68) | (3.04) |
| Upside | -100.9% - -101.2% | -101.0% |
| Date | EV/EBITDA |
| 2025-07-08 | -854.34 |
| 2025-07-07 | -872.18 |
| 2025-07-03 | -893.11 |
| 2025-07-02 | -887.35 |
| 2025-07-01 | -866.61 |
| 2025-06-30 | -877.45 |
| 2025-06-27 | -868.68 |
| 2025-06-26 | -856.36 |
| 2025-06-25 | -866.29 |
| 2025-06-24 | -874.52 |
| 2025-06-23 | -842.58 |
| 2025-06-20 | -833.35 |
| 2025-06-18 | -840.40 |
| 2025-06-17 | -830.69 |
| 2025-06-16 | -830.88 |
| 2025-06-13 | -828.75 |
| 2025-06-12 | -819.82 |
| 2025-06-11 | -803.44 |
| 2025-06-10 | -813.88 |
| 2025-06-09 | -818.02 |
| 2025-06-06 | -809.49 |
| 2025-06-05 | -828.78 |
| 2025-06-04 | -821.54 |
| 2025-06-03 | -817.40 |
| 2025-06-02 | -823.64 |
| 2025-05-30 | -819.53 |
| 2025-05-29 | -788.15 |
| 2025-05-28 | -768.41 |
| 2025-05-27 | -780.62 |
| 2025-05-23 | -780.25 |
| 2025-05-22 | -777.66 |
| 2025-05-21 | -787.29 |
| 2025-05-20 | -784.87 |
| 2025-05-19 | -785.36 |
| 2025-05-16 | -767.73 |
| 2025-05-15 | -762.60 |
| 2025-05-14 | -719.95 |
| 2025-05-13 | -718.10 |
| 2025-05-12 | -727.05 |
| 2025-05-09 | -675.83 |
| 2025-05-08 | -695.20 |
| 2025-05-07 | -744.17 |
| 2025-05-06 | -726.03 |
| 2025-05-05 | -736.09 |
| 2025-05-02 | -698.00 |
| 2025-05-01 | -686.54 |
| 2025-04-30 | -708.36 |
| 2025-04-29 | -692.08 |
| 2025-04-28 | -685.78 |
| 2025-04-25 | -676.93 |